Survival, growth and spread of tumors depend upon an adequate blood supply ensured by neovascularization, cooption of existing vessels and stem cell differentiation into endothelial cells. Thus, inhibitors of angiogenesis may represent novel tools for the treatment of cancer. We observed that supernatants of EBV-immortalized cell generally contain inhibitors of endothelial cells proliferation. From supernatants of the lymphoblastic VDS-O cell line we purified an endothelial cell inhibitor, and identified it as a mixture of NH2-terminal fragments of calreticulin. The recombinant purified NH2-terminal fragments of calreticulin (amino acids 1-180) inhibited the proliferation of endothelial cells but not the proliferation of cells of other lineages, and suppressed angiogenesis in vivo. We have named this NH2-terminal domain of calreticulin vasostatin. When inoculated into athymic mice, vasostatin reduced growth of Burkitt lymphoma, colon carcinoma, breast adenocarcinoma, melanoma, rhabdomyosarcoma, lung adenocarcinoma and Wilms tumors. Full-length calreticulin, calreticulin lacking the NH2 terminal 1-120 amino acids, and an internal calreticulin fragment encompassing amino acids 120-180 inhibited endothelial cell proliferation, angiogenesis, and tumor growth in vivo comparably to vasostatin. These results suggest that the antiangiogenic and antitumor activities of vasostatin reside in a domain that is accessible from the full-length calreticulin molecule and localized to an internal 61 amino acids fragment within the NH2 domain of calreticulin. Thus, we have identified calreticulin and vasostatin as novel angiogenesis inhibitors that suppress tumor growth in preclinical tumor models.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC010355-01
Application #
6421054
Study Section
(MB)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Salvucci, Ombretta; Maric, Dragan; Economopoulou, Matina et al. (2009) EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood 114:1707-16
Nakayama, Takayuki; Mutsuga, Noriko; Tosato, Giovanna (2007) FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood 109:1363-72
Huegel, Rainer; Velasco, Paula; De la Luz Sierra, Maria et al. (2007) Novel anti-inflammatory properties of the angiogenesis inhibitor vasostatin. J Invest Dermatol 127:65-74
Narazaki, Masashi; Tosato, Giovanna (2006) Tumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us why. J Natl Cancer Inst 98:294-5
Salvucci, Ombretta; de la Luz Sierra, Maria; Martina, Jose A et al. (2006) EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. Blood 108:2914-22
Narazaki, Masashi; Tosato, Giovanna (2006) Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth? J Natl Cancer Inst 98:726-7
Narazaki, Masashi; Tosato, Giovanna (2006) Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood 107:3892-901
Narazaki, Masashi; Tosato, Giovanna (2006) Canstatin: an inhibitor of angiogenesis and tumor growth revisited. Cancer J 12:110-2
Nakayama, Takayuki; Mutsuga, Noriko; Yao, Lei et al. (2006) Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. J Leukoc Biol 79:95-104